A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug. The studies presented a number of critical challenges to the PRA project team. Through teamwork and strategic planning, PRA developed plans that helped us reach the client’s milestones and resulted in successful site activations and first patient in.
Persistence Leads To High Enrollment
A Phase IV, randomized, single-blind, placebo-controlled, multi-center study to evaluate the immunogenicity of pneumococcal and influenza vaccines in…
PRA Health Sciences Investor Relations
At PRA, Medical Directors have the unique opportunity to impact a broad patient population while staying focused on their therapeutic area of…